Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2Phase 4 1Phase 3 1Phase 2/3 1

Status

Completed 58Terminated 13Unknown 6Recruiting 5Not yet recruiting 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Unresectable Locally Advanced or Metastatic Solid Tumors 1Colorectal Neoplasms 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9venetoclax 7toripalimab 7pembrolizumab 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7irinotecan sucrosofate 6Temozolomide 6Fluorouracil 6tislelizumab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5HMPL-013 5Etoposide 5Dexamethasone 5Cisplatin 5Carboplatin 5Capecitabine 5Biopsy 5sintilimab 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Everolimus × Clear all
NCT07435584 2026-02-27

EVER-RECODE

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1/2 Not yet recruiting
38 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Phase 1/2 Not yet recruiting
380 enrolled
Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡